Immunocal

Product Information

Immunocal preserves CGN viability and protects from apoptosis after exposure to SNP. (a) Representative images of CGNs left untreated (control), treated with SNP (100 μM), or preincubated with Immunocal for 24h before SNP treatment for further 24h. Immunofluorescence shows β-tubulin (green) and DAPI (blue). Scale bar, 10 μm. (b) Quantification of apoptosis for 5 independent experiments performed as in (a). Results are shown as mean±SEM, n = 5. (c) MTT cell viability was measured as described in Materials and Methods. Results are shown as mean±SEM, n = 3. For (b) and (c), ∗∗∗ indicates p< 0.001 compared to control, and ††† indicates p< 0.001 compared to SNP. Con: control; ICAL: Immunocal. Lothian B, Grey V, Kimoff RJ, Lands. Treatment of obstructive airway disease with a cysteine donor protein supplement: a case report. Chest 117:914-916, 2000 Each type of cancer is unique. Immunotherapy doesn’t work for all types of cancer or for all people with cancer. But doctors continue to test new treatments.

Locigno R, Castronovo V. Reduced glutathione System: Role in cancer development, prevention and treatment. International Journal of Oncology 19:221-236, 2001 Targeted antibodies. This type of treatment disrupts cancer cells and alerts the immune system to target and kill them.There are a few ways to get cysteine into the body, but only one proven way to get it into your cells to make glutathione – and that is a chemical found in human breast milk! Given the prominent relationship between GSH depletion and neurodegeneration, it is not surprising that many studies have been undertaken to determine the neuroprotective effects of bolstering GSH levels through various treatment paradigms. Such treatments include administration of the GSH precursor, N-acetylcysteine (NAC), and GSH-monoethylester (GSH-MEE), a cell permeable form of GSH, and induction of the transcription factor, nuclear factor erythroid 2-related factor-2 (Nrf2), which is involved in transcriptional regulation of γ-glutamyl-cysteine ligase, the rate-limiting enzyme necessary for GSH synthesis [ 19]. Studies with NAC are extensive and indicate that NAC treatment offers a number of benefits across numerous disease models. For example, NAC demonstrated a significant protective capacity in a rotenone (complex I inhibition) rat model of Parkinson's disease by decreasing ROS generation, sustaining normal GSH levels, and ultimately preventing dopaminergic cell death [ 20]. In the G93A mutant SOD1 mouse model of familial ALS, NAC delayed the onset of disease-associated motor deficits and significantly extended survival, possibly due to its ability to elevate GSH levels in these animals [ 21]. Lastly, SAMP8 senescence-accelerated mice, which display many of the pathological features of Alzheimer's disease, demonstrated an increased cognitive performance with NAC treatment as compared to vehicle-treated controls [ 22]. Another study utilizing GSH-MEE in an MPTP rat model of Parkinson's disease demonstrated that GSH-MEE supplementation is capable of raising GSH levels in the brain when centrally delivered, and this increase in GSH corresponded to partial preservation of striatal dopamine levels [ 23]. Studies such as this have led to recent clinical trials testing the safety and tolerability of intranasal delivery of GSH to patients with PD [ 24]. Finally, Nrf2 induction or overexpression has shown similar promise in animal models of Parkinson's, ALS, and Alzheimer's disease. In the MPTP mouse model of Parkinson's disease, overexpression of Nrf2 in astrocytes attenuated the development of a Parkinsonian phenotype [ 25]. Likewise, astrocytic overexpression of Nrf2 in a mouse model of ALS both delayed onset and increased survival, as did treatment with chemical Nrf2 inducers [ 26, 27]. Comparatively, lentiviral Nrf2 overexpression caused significant improvements in observed learning deficits in a mouse model of Alzheimer's disease, accompanied by decreased amyloid plaque burden [ 28]. Cumulatively, these data indicate that treatments aimed at increasing GSH levels in the brain may be a viable option for treatment and prevention of neurodegenerative disease. If you need guidance on how to bottle feed crias, please see our Feeding Guide for Crias. What makes Immucol Platinum so good? Dr Luc Montagnier, winner of the 2008 Nobel Prize in Medicine, for his discovery of HIV, “Glutathione is of major significance in cellular antioxidant activity, and that Immunocal functioning as a cysteine delivery system can enhance glutathione synthesis…”

Vitamins A, D3, E, B1, B2, B6 and B12, Vitamin K3, Vitamin C, Niacin, Folic acid, Biotin, Calcium, Sodium, Phosphorus, Potassium, Sulphur, Selenium, Cobalt, Iodine, Manganese, Zinc and Iron Treatment vaccines, which work against cancer by boosting your immune system’s response to cancer cells. Treatment vaccines are different from the ones that help prevent disease. To determine if the protective action of Immunocal observed in CGNs was reproducible in other neuronal cell types bearing relevance to neurodegenerative disease, we examined the capacity of this supplement to protect NSC34 motor neuron-like cells from oxidative stress and excitotoxicity. NSC34 cells are a hybrid cell line consisting of spinal cord motor neurons fused with mouse neuroblastoma cells [ 64]. We first analyzed the ability of Immunocal to protect NSC34 cells from H 2O 2-induced oxidative stress. Immunocal pretreatment of NSC34 cells dose-dependently attenuated H 2O 2-induced cell death. We next examined the potential of Immunocal to ameliorate damage induced by excitotoxic insult in NSC34 cells, which were differentiated by prolonged serum withdrawal to induce the expression of NMDA receptors [ 47]. Excitotoxicity is known to play a prevalent role in the pathogenesis of multiple neurodegenerative diseases, including ALS, and is intimately linked with both oxidative and nitrosative stress [ 65]. Immunocal pretreatment of differentiated NSC34 motor neuron-like cells significantly reduced the injurious effects of glutamate excitotoxicity in a dose-dependent manner.IMMUNOCAL is a dehydrated powdered protein isolate. It must be appropriately rehydrated before use. Remains bioactive up to 12 hours after mixing. DO NOT heat or use a hot liquid to rehydrate the product. DO NOT use a high-speed blender for reconstitution. These methods will decrease the activity of the product. Finally I am pleased to report all the cria have gone on to thrive and enjoy life on the farm without having any further issues. The research lead to the development of a product called Immunocal, which is widely recognised in the medical community as being a great immune booster. Agrimin Bimeda Boehringer Ingelheim CEVA Chanelle Elanco MSD Nettex Norbrook Zoetis All Manufacturers

Andersson and his colleagues harvested blood from 44 people with fibromyalgia and injected purified antibodies from each of them into different mice. The mice rapidly became more sensitive to pressure and cold, and displayed reduced grip strength in their paws. Animals injected with antibodies from healthy people were unaffected.Bounous G. Immunoenhancing properties of undenatured milk serum protein isolate in HIV patients. Int. Diary Fed: Whey: 293-305, 1998 Please note there is a small excess for despatch to Highlands and Islands and Isle of Wightas governed by your postcode. Prof Camilla Svensson from the Karolinska Institute in Sweden, who was also involved in the study, said: “Antibodies from people with fibromyalgia living in two different countries, the UK and Sweden, gave similar results, which adds enormous strength to our findings.”

Glutathione is a tripeptide made intracellularly from its constituent amino acids L-glutamate, L-cysteine and glycine. The sulfhydryl (thiol) group (SH) of cysteine serves as a proton donor and is responsible for the biological activity of glutathione. Provision of this amino acid is the rate-limiting factor in glutathione synthesis by the cells since cysteine is relatively rare in foodstuffs and furthermore, if released as the free amino acid, is toxic and spontaneously catabolized in the gastrointestinal tract and blood plasma. The development of new therapies has also been hampered by a limited scientific understanding of what causes the condition in the first place, but this could change with the discovery that the immune system is involved. A broad Spectrum of Vitamins and Minerals are supplied at the correct levels to help support strong development and growth.According to the most recent recommendations, screening for prediabetes and diabetes should begin at the age of 35 years [ 26]. The previous recommendation was that testing should begin at the age of 45 years. This change reflects the findings that opportunistic universal screening among individuals aged ≥35 years could greatly reduce the national prevalence of undiagnosed prediabetes or diabetes at a relatively low cost. In the glycemic assessment section, TIR along with A1C has been more fully incorporated into the guideline [ 27]. A 14-day CGM assessment of TIR and use of a glucose management indicator can serve as a surrogate for A1C in clinical management. Cells treated with Immunocal display healthy neuronal morphology. Cells were left untreated (a) or treated with Immunocal alone (b) and assessed for overall health and appearance. Left-hand panels are representative images of cell nuclei stained with DAPI. Right-hand panels depict the same fields as viewed under brightfield to assess the state of neuronal processes and soma. Con: control; ICAL: Immunocal. Scale bar, 10 μm. Baruchel S, Viau G, Olivier R. et al. Nutraceutical modulation of glutathione with a humanized native milk serum protein isolate, Immunocal: application in AIDS and cancer. In : Oxidative Stress in Cancer, AIDS and Neurodegenerative Diseases. Ed.; Montagnier L, Olivier R, Pasquier C. Marcel Dekker Inc. New York, 447-461, 1998 Immunotherapy is a cancer treatment that helps your own immune system beat cancer. That’s different than traditional chemotherapy, which uses drugs that kill both cancer and healthy cells. The American Diabetes Association (ADA) releases updated Standards of Medical Care in Diabetes every year in January [ 24]. Recent updates have focused on individualization of diabetes management in screening, intervention and care, use of technology, and prevention of complications [ 25]. Patient-centered care goals were emphasized in preventing type 2 DM. Overweight and obese adults at high-risk of type 2 DM are recommended to be referred to an intensive lifestyle and behavior change program. Individualized management of overweight and obese adults was also emphasized to prevent diabetes and comorbidities [ 26]. With developments of technology, it was recommended to consider technological assistance according to the individual’s preference [ 27].